Prime Editing Unlocks a Universal Strategy for Restoring Lost Proteins
November 22, 2025
Free CME credits
Both our subscription plans include Free CME/CPD AMA PRA Category 1 credits.
Brand Name :
Mavenclad
(United States) [Available]Synonyms :
Class :
Anticancer and antimetabolites
Brand Name :
Mavenclad
(United States) [Available]Synonyms :
Class :
Anticancer and antimetabolites
Dosage forms & Strengths
Solution
10 mg/10 ml
Tablet
10 mg
5
mg/m^2
Intravenous (IV)
5
days
daily infused over 3 hours, generally given in combination with daunorubicin and cytarabine
CLAG regimen:
5
mg/m^2
Intravenous (IV)
Over 2 hr
5
days
given in combination with cytarabine, filgrastim and mitoxantrone
0.09 - 0.1
mg/kg
Intravenous (IV)
continuous infusion
7
days
or 0.15 mg/kg/day IV over 2 hr for 5 days in combination with rituximab
5
mg/m^2
Intravenous (IV)
Over 2 hr
5
days
every 4 weeks as cycle 1, continue till 2 to 6 cycles
1.75
mg/kg
Oral
per year for a total dose of 3.5 mg/kg over 2 years (NMT 20mg/day)
0.1
mg/kg
Intravenous (IV)
once a day
7
days
every 4 weeks or 0.1 mg/kg SUBQ per day for 5 days every month in combination with rituximab
Dose Adjustments
CrCl 10 to 50 ml/minute: administer 75% of dose
CrCl <10 ml/minute: administer 50% of dose
CAPD: administer 50% of dose
CrCl > 60 ml/minute: no dosage adjustment necessary
CrCl < 60 ml/minute: use is not recommended
Hemodialysis: use is not recommended
eGFR <50 ml/minute: use not recommended
For moderate to severe hepatic impairment: use is not recommended
Dosage forms & Strengths Â
Solution Â
10 mg/10 ml Â
Tablet Â
10 mg Â
Children and adolescents:
8.9
mg/m^2
Intravenous (IV)
once a day
5
days
Children and adolescents:
5
mg/m^2
Intravenous (IV)
once a day
over 2 hrs for 5 days for a 21-day cycle
cladribine: they may decrease the therapeutic effect of hormonal contraceptives
cladribine: they may decrease the therapeutic effect of hormonal contraceptives
cladribine: they may decrease the therapeutic effect of hormonal contraceptives
cladribine: they may decrease the therapeutic effect of hormonal contraceptives
cladribine: they may diminish the serum concentration of hormonal contraceptives
cladribine: they may diminish the serum concentration of hormonal contraceptives
cladribine: they may diminish the serum concentration of hormonal contraceptives
cladribine: they may decrease the therapeutic effect of vaccines
measles, mumps, rubella, and varicella vaccine, live 
cladribine: they may decrease the therapeutic effect of vaccines
measles mumps and rubella vaccine, live
cladribine: they may decrease the therapeutic effect of vaccines
cladribine: they may decrease the therapeutic effect of vaccines
smallpox (vaccinia) vaccine, live
cladribine: they may decrease the therapeutic effect of vaccines
may enhance the serum concentration
may enhance the serum concentration of BRCP/ABCG2 inhibitors
may enhance the serum concentration of BCRP/ABCG2 inhibitors
may enhance the serum concentration of BCRP/ABCG2 inhibitors
may enhance the serum concentration of BCRP/ABCG2 inhibitors
may enhance the serum concentration of BCRP/ABCG2 Inhibitors
meningococcal A C Y and W polysaccharide tetanus toxoid conjugate vaccineÂ
vaccination should be given at least 14 days before initiation of cladribine to avoid a reduction in the efficacy of the vaccines
may increase excessive immunosuppressive effects and risk of infection
adenovirus types and live oral
may reduce therapeutic effects of the vaccine
increase immunosuppressive effects and risk of infection
increase immunosuppressive effects and risk of infection
increase immunosuppressive effects and risk of infection
clozapine
increase immunosuppressive effects and risk of infection
may raise the risk of pancytopenia and agranulocytosis due to myelosuppression
may increase bone marrow suppression
increases the serum concentration of BCRP/ABCG2 substrates
increase immunosuppressive effects and risk of infection
increase immunosuppressive effects and risk of infection
increase toxic adverse effects of cladribine
may increase bone marrow suppression
may increase bone marrow suppression
increase immunosuppressive effects and risk of infection
immunosuppressants increase the effect of immunosuppression of cladribine
immunosuppressants increase the effect of immunosuppression of cladribine
immunosuppressants increase the effect of immunosuppression of cladribine
immunosuppressants increase the effect of immunosuppression of cladribine
immunosuppressants increase the effect of immunosuppression of cladribine
may have an increased immunosuppressive effect when combined with cladribine
may have an increased immunosuppressive effect when combined with cladribine
may have an increased immunosuppressive effect when combined with cladribine
may have an increased immunosuppressive effect when combined with cladribine
may have an increased immunosuppressive effect when combined with cladribine
cladribine: they may increase the immunosuppressive effect of immunostimulants
cladribine: they may increase the immunosuppressive effect of immunostimulants
cladribine: they may increase the immunosuppressive effect of immunostimulants
cladribine: they may increase the immunosuppressive effect of immunostimulants
cladribine: they may increase the immunosuppressive effect of immunostimulants
cladribine: they may increase the myelosuppressive effect of myelosuppressive agents
antiretroviral agents undergo intracellular phosphorylation that will reduce the efficacy of cladribine
antiretroviral agents undergo intracellular phosphorylation that will reduce the efficacy of cladribine
antiretroviral agents undergo intracellular phosphorylation that will reduce the efficacy of cladribine
antiretroviral agents undergo intracellular phosphorylation that will reduce the efficacy of cladribine
cladribine: they may increase the immunosuppressive effect of selective immunosuppressants
cladribine: they may increase the immunosuppressive effect of selective immunosuppressants
cladribine: they may increase the immunosuppressive effect of selective immunosuppressants
when both drugs are combined, there may be an increased risk or severity of adverse effects   
when both drugs are combined, there may be an increased risk or severity of adverse effects   
when both the drugs are combined, the risk or severity of adverse effects increases    
immunosuppressants such as doxorubicin may enhance the immunosuppressive effect of another drug
when both drugs are combined, there may be an increased risk or severity of adverse effects   
when both drugs are combined, there may be an increased risk of serious infections   
when both drugs are combined, there may be an increased risk of serious infections  
high-risk for serious infections due to increasing immunosuppression
high-risk for serious infections due to increasing immunosuppression
immunosuppressants such as doxorubicin may enhance the immunosuppressive effect of another drug
when both drugs are combined, the risk or severity of adverse effects increases  
when both drugs are combined, there may be an increased risk or severity of adverse effects   
when both drugs are combined, there may be an increased risk or severity of adverse effects  
when both drugs are combined, there may be an increased risk or severity of adverse effects  
may increase myelosuppression and immunosuppression
when both drugs are combined, there may be a decreased therapeutic effect of the vaccine  
when both drugs are combined, there may be an increase in the risk of the myelosuppressive effect of myelosuppressive agents  
it may increase the bone marrow suppression effect of cladribine
when both drugs are combined, there may be an increase in immunosuppressive activity and the risk of severe infection
when both drugs are combined, there may be an increase in the myelosuppressive effect
it enhances the myelosuppressive activity of cladribine
the effect of myelosuppression is increased in myelosuppressive agents
it increases the effect of myelosuppression in myelosuppressive agents
immunosuppressants such as doxorubicin may enhance the immunosuppressive effect of another drug
may increase the immunosuppressive effects
may increase the immunosuppressive effect
may increase the immunosuppressive effects
may increase the toxic effect
may increase the toxic effect
may increase the immunosuppressive effect of corticosteroids
may increase the immunosuppressive effect of immunosuppressants
may increase the myelosuppressive effect of myelosuppressive agents
may increase the myelosuppressive effect of myelosuppressive agents
may increase the myelosuppressive effect of myelosuppressive agents
may increase the myelosuppressive effect of myelosuppressive agents
may increase the immunosuppressive effect of Immunosuppressive agents
may increase the myelosuppressive effect of Myelosuppressive Agents
may increase the myelosuppressive effect of Myelosuppressive Agents
may increase the immunosuppressive effect of Immunosuppressants
may increase the myelosuppressive effect of Myelosuppressive Agents
increase immunosuppressive effects and risk of infection
may diminish immune response to cholera vaccine
may diminish immune response to dengue vaccine
increased risk of serious infection due to impaired immune system
may manifest acute “recall” pneumonitis after radiation therapy
cladribine increases the effects of fingolimod and the risk of infection by immunosuppressive effects
interaction may increase the risk of bone marrow suppression
increase serum levels by increasing p-glycoprotein efflux transporter
increases immunosuppressive effects and risk of infection
may increase myelosuppression and immunosuppression
may increase excessive immunosuppressive effects
may diminish therapeutic effects of sipuleucel-T
trastuzumab: may enhance the risk of neutropenia due to immunosuppression
may have an increased myelosuppressive effect when combined with myelosuppressive agents
may have an increased myelosuppressive effect when combined with myelosuppressive agents
may have an increased myelosuppressive effect when combined with myelosuppressive agents
may have an increased myelosuppressive effect when combined with myelosuppressive agents
may have an increased myelosuppressive effect when combined with myelosuppressive agents
may have an increased immunosuppressive effect when combined with cladribine
may have an increased immunosuppressive effect when combined with cladribine
may have an increased immunosuppressive effect when combined with cladribine
When mometasone furoate is used together with cladribine, this leads to enhanced risk or seriousness of adverse outcomes
When cladribine is used together with andrographolide, this leads to enhanced risk or seriousness of bleeding
cladribine: it may increase the risk of bleeding with trapidil
may enhance the adverse effects of bone marrow suppression
may increase the risk of excessive bone marrow suppression
It may decrease the therapeutic efficacy of cladribine
May decrease the therapeutic effects of cladribine
immunosuppressants (therapeutic immunosuppressant agents) may enhance the immunosuppressive effect of cladribine. risk x: avoid combination 
Actions and spectrum:Â Â
Cladribine may be completed its resistance to adenosine deaminase (ADA) deamination by substituting chorine atom for H- atom at second position of purine ring. Â
Frequency defined:Â Â
>10%:Â
Fever Â
Fatigue Â
Headache Â
VomitingÂ
Rash  Â
Headache Â
Lymphopenia Â
Upper respiratory tract infection Â
1-10%Â Â
Diarrhea Â
Insomnia Â
Bronchitis Â
Depression Â
<1%:Â
Pancytopenia Â
Seizures Â
Fungal infection Â
Black Box Warning  Â
None Â
Contraindication/Caution:Â Â
Contraindication:Â Â
Hypersensitivity Â
Malignancy Â
HIV infectionÂ
Pregnancy Warnings:Â
Pregnancy category: N/AÂ
Lactation:Â
Excretion of the drug into the human breast milk is unknownÂ
Pregnancy categories:Â
Category A: Satisfactory and well-controlled studies show no evidence of risk to the fetus in the first trimester or in the later trimester.Â
Category B: No evidence of risk to fetus found in animal reproduction studies and there are not enough studies on pregnant women.Â
Category C: Adverse effects on the fetus found with evidence in animal reproduction studies and no adequate evidence for an effect in humans, care must be taken for potential risks in pregnant women.Â
Category D: There is adequate data available with sufficient evidence of human fetal risk from various platforms, but despite potential risks may be used only in emergency cases for potential benefits.Â
Category X: Drugs listed in this category clearly outweigh risks over benefits. These category drugs should be prohibited for pregnant women.Â
Category N: There is no data available for the drug under this category.Â
Pharmacology:Â Â
It belongs to synthetic purine nucleus that suppresses the immune system and functions as an antineoplastic agent.Â
Pharmacodynamics:Â Â
Cladribine is structurally identical to pentostatin and fludarabine. Â
Pharmacokinetics:Â Â
Limited information is available on ADME. Â
Administration:Â Â
Cladribine taken orally and administered intravenously. Â
Generic Name: cladribineÂ
Pronounced: KLA-dri-beenÂ
Why do we use cladribine?Â
Cladribine is used to treat hairy cell leukemia, a rare type of white blood cell cancer. It belongs to a class of drugs called purine analogs and works by slowing or stopping the growth of cancer cells.Â
Both our subscription plans include Free CME/CPD AMA PRA Category 1 credits.
On course completion, you will receive a full-sized presentation quality digital certificate.
A dynamic medical simulation platform designed to train healthcare professionals and students to effectively run code situations through an immersive hands-on experience in a live, interactive 3D environment.
When you have your licenses, certificates and CMEs in one place, it's easier to track your career growth. You can easily share these with hospitals as well, using your medtigo app.
